Φορτώνει......
Omalizumab for severe asthma: toward personalized treatment based on biomarker profile and clinical history
Asthma is a heterogeneous syndrome with numerous underlining molecular and inflammatory mechanisms contributing to the wide spectrum of clinical phenotypes. Multiple therapies targeting severe asthma with type 2 (T2) high inflammation are or soon will be available. T2 high inflammation is defined as...
Αποθηκεύτηκε σε:
| Τόπος έκδοσης: | J Asthma Allergy |
|---|---|
| Κύριοι συγγραφείς: | , |
| Μορφή: | Artigo |
| Γλώσσα: | Inglês |
| Έκδοση: |
Dove Medical Press
2018
|
| Θέματα: | |
| Διαθέσιμο Online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5892947/ https://ncbi.nlm.nih.gov/pubmed/29662320 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/JAA.S107982 |
| Ετικέτες: |
Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!
|